Methods of treatment using TLR7 and/or TLR9 inhibitors
Inventors
Barrat, Franck • Coffman, Robert L. • Guiducci, Cristiana
Assignees
Interested in licensing this patent?
MTEC can help explore whether this patent might be available for licensing for your application.
Abstract
The application relates to compositions and methods of regulating an immune response comprising inhibitors of TLR7 and/or TLR9, such as immunoregulatory polynucleotides and/or immunoregulatory compounds. The application also relates to compositions and methods for predicting and/or determining responsiveness of a disease to treatment comprising inhibitors of TLR7 and/or TLR9.
Core Innovation
The claimed invention relates to immunoregulatory polynucleotides that inhibit TLR7 and TLR9 signaling to suppress immune responses and treat autoimmune or inflammatory diseases. The method comprises administering to an individual an effective amount of a polynucleotide consisting of SEQ ID NO:73, SEQ ID NO:134, SEQ ID NO:143, or SEQ ID NO:144 containing phosphorothioate linkages. The disclosure additionally encompasses monitoring responses and selecting treatments using inflammatory gene expression, interferon signatures, or cytokine levels.
The reported polynucleotide sequences demonstrate low B-cell stimulatory activity, favorable toxicity, and reduced inflammatory gene expression and cutaneous lesions in lupus-prone disease models. Documented evaluations include corticosteroid-sparing applications in lupus models, associations between reduced interferon signatures and glucocorticoid pulse therapy, and immune-response outcomes under various treatment conditions. Because background content is omitted from the supplied text, the specific problem addressed is not explicitly described in the patent.
Claims Coverage
The provided claims identify one independent claim comprising two inventive features.
Treatment of autoimmune or inflammatory disease
A method of treating an individual having an autoimmune disease or an inflammatory disease by administering an effective amount of a polynucleotide.
Specified phosphorothioate-linked polynucleotide
The polynucleotide consists of a nucleotide sequence selected from SEQ ID NO:73, SEQ ID NO:134, SEQ ID NO:143, and SEQ ID NO:144, and contains phosphorothioate linkages.
The independent claim covers treating an autoimmune or inflammatory disease by administering an effective amount of one of four specified phosphorothioate-linked polynucleotides, with dependent claims addressing specific diseases including systemic sclerosis and pancreatitis, pharmaceutical compositions, sterile isotonic solutions, and single-stranded forms.
Stated Advantages
Selected polynucleotide sequences are reported to exhibit low B-cell stimulatory activity and comparatively favorable toxicity.
In lupus-prone models, the dual TLR7/9 inhibitor reduced inflammatory gene expression and ameliorated or resolved cutaneous lesions, including when treatment began after lesions developed.
Human systemic lupus erythematosus data associate reduced interferon signatures with intravenous glucocorticoid pulse therapy.
Documented Applications
Treatment of autoimmune or inflammatory diseases, including systemic lupus erythematosus, systemic sclerosis, pancreatitis, and cutaneous lesions associated with cutaneous lupus erythematosus.
Corticosteroid-sparing applications in lupus models.
Treatment selection and response monitoring using elevated inflammatory gene expression, interferon signatures, or cytokine levels.
A proposed clinical trial of an immunoregulatory sequence in systemic lupus erythematosus.
Interested in licensing this patent?